BSW
TEVA icon

Buckingham Strategic Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Buckingham Strategic Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$523K Buy
32,169
+1,009
+3% +$15.5K 0.01% 457
2024
Q1 		$440K Sell
31,160
-2
-0% -$25 ﹤0.01% 499
2023
Q4 		$325K Sell
31,162
-52
-0.2% -$485 ﹤0.01% 552
2023
Q3 		$318K Buy
31,214
+52
+0.2% +$484 ﹤0.01% 513
2023
Q2 		$235K Sell
31,162
-48
-0.2% -$389 ﹤0.01% 589
2023
Q1 		$285K Hold
31,210
– – 0.01% 493
2022
Q4 		$285K Sell
31,210
-700
-2% -$6.11K 0.01% 495
2022
Q3 		$258K Sell
31,910
-239
-0.7% -$2.11K 0.01% 500
2022
Q2 		$242K Buy
32,149
+200
+0.6% +$1.74K ﹤0.01% 513
2022
Q1 		$300K Buy
31,949
+910
+3% +$7.59K 0.01% 473
2021
Q4 		$249K Sell
31,039
-906
-3% -$8.18K ﹤0.01% 520
2021
Q3 		$311K Buy
31,945
+746
+2% +$6.99K 0.01% 460
2021
Q2 		$309K Buy
31,199
+124
+0.4% +$1.31K 0.01% 460
2021
Q1 		$359K Sell
31,075
-25
-0.1% -$287 0.02% 398
2020
Q4 		$300K Hold
31,100
– – 0.02% 419
2020
Q3 		$280K Buy
31,100
+11,000
+55% +$116K 0.02% 386
2020
Q2 		$248K Sell
20,100
-6,100
-23% -$69K 0.02% 349
2020
Q1 		$235K Sell
26,200
-263
-1% -$2.69K 0.02% 395
2019
Q4 		$259K Sell
26,463
-1,383
-5% -$12.3K 0.02% 388
2019
Q3 		$192K Sell
27,846
-608
-2% -$4.66K 0.02% 408
2019
Q2 		$263K Buy
28,454
+2,256
+9% +$27.2K 0.03% 364
2019
Q1 		$411K Hold
26,198
– – 0.05% 262
2018
Q4 		$404K Buy
26,198
+458
+2% +$9.39K 0.06% 219
2018
Q3 		$554K Buy
25,740
+17,442
+210% +$405K 0.09% 178
2018
Q2 		$202K Buy
+8,298
New +$169K 0.03% 343
2017
Q3 		– Sell
-17,820
Closed -$592K – 307
2017
Q2 		$592K Buy
+17,820
New +$552K 0.14% 138
2015
Q3 		– Sell
-4,408
Closed -$261K – 229
2015
Q2 		$261K Buy
+4,408
New +$272K 0.09% 175

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Buckingham Strategic Wealth's TEVA Position: Q2 2024 in Review

Buckingham Strategic Wealth increased its Teva Pharmaceuticals (TEVA) stake by 3.2% in Q2 2024, buying an estimated $15.5K and bringing the position to 32,169 shares worth $523K. The position accounts for 0.01% of the portfolio, ranked #457.

Buckingham Strategic Wealth first reported a position in TEVA in Q2 2015 and has held it in 27 quarters since. The position peaked at $592K in Q2 2017. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Buckingham Strategic Wealth held 32,169 shares of Teva Pharmaceuticals worth $523K as of Q2 2024.
  • Buckingham Strategic Wealth bought 1,009 Teva Pharmaceuticals shares in Q2 2024, an estimated $15.5K.
  • Teva Pharmaceuticals made up 0.01% of Buckingham Strategic Wealth's portfolio in Q2 2024, its #457 holding.
  • Buckingham Strategic Wealth first reported a position in Teva Pharmaceuticals in Q2 2015 and has held it in 27 quarters since.
  • Buckingham Strategic Wealth's Teva Pharmaceuticals position peaked at $592K in Q2 2017.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.